{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:27:56Z","timestamp":1790638076016,"version":"4.1.0"},"reference-count":105,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCDD"],"abstract":"<jats:p>Hypertension is the most frequent chronic and non-communicable disease all over the world, with about 1.5 billion affected individuals worldwide. Its impact is currently growing, particularly in low-income countries. Even in high-income countries, hypertension remains largely underdiagnosed and undertreated, with consequent low rates of blood pressure (BP) control. Notwithstanding the large number of clinical observational studies and randomized trials over the past four decades, it is sad to note that in the last few years there has been an impressive paucity of innovative studies. Research focused on BP mechanisms and novel antihypertensive drugs is slowing dramatically. The present review discusses some advances in the management of hypertensive patients, and could play a clinical role in the years to come. First, digital\/health technology is expected to be increasingly used, although some crucial points remain (development of non-intrusive and clinically validated devices for ambulatory BP measurement, robust storing systems enabling rapid analysis of accrued data, physician-patient interactions, etc.). Second, several areas should be better outlined with regard to BP diagnosis and treatment targets. Third, from a therapeutic standpoint, existing antihypertensive drugs, which are generally effective and well tolerated, should be better used by exploiting available and novel free and fixed combinations. In particular, spironolactone and other mineral-corticoid receptor antagonists should be used more frequently to improve BP control. In particular, some drugs initially developed for conditions different from hypertension including heart failure and diabetes have demonstrated to lower BP significantly and should therefore be considered. Finally, renal artery denervation is another procedure that has proven effective in the management of hypertension.<\/jats:p>","DOI":"10.3390\/jcdd9030072","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T09:24:53Z","timestamp":1646299493000},"page":"72","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Advances in the Treatment Strategies in Hypertension: Present and Future"],"prefix":"10.3390","volume":"9","author":[{"given":"Paolo","family":"Verdecchia","sequence":"first","affiliation":[{"name":"Fondazione Umbra Cuore e Ipertensione-ONLUS, 06100 Perugia, Italy"},{"name":"Division of Cardiology, Hospital S. Maria della Misericordia, 06100 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Cavallini","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Hospital S. Maria della Misericordia, 06100 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4925-7985","authenticated-orcid":false,"given":"Fabio","family":"Angeli","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Insubria, 21100 Varese, Italy"},{"name":"Department of Medicine and Cardiopulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri\u2014IRCCS of Tradate, 21049 Tradate, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","article-title":"Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries","volume":"134","author":"Mills","year":"2016","journal-title":"Circulation"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1161\/HYPERTENSIONAHA.114.04310","article-title":"Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease","volume":"65","author":"Verdecchia","year":"2015","journal-title":"Hypertension"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1161\/HYPERTENSIONAHA.113.02089","article-title":"Tight versus standard blood pressure control in patients with hypertension with and without cardiovascular disease","volume":"63","author":"Reboldi","year":"2014","journal-title":"Hypertension"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/HJH.0000000000000112","article-title":"Hypertension, inflammation and atrial fibrillation","volume":"32","author":"Angeli","year":"2014","journal-title":"J. Hypertens."},{"key":"ref_5","unstructured":"NCD Risk Factor Collaboration (NCD-RisC) (2017). Worldwide trends in blood pressure from 1975 to 2015: A pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet, 389, 37\u201355."},{"key":"ref_6","unstructured":"NCD Risk Factor Collaboration (NCD-RisC) (2021). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. Lancet, 398, 957\u2013980."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2016.19043","article-title":"Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990\u20132015","volume":"317","author":"Forouzanfar","year":"2017","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/HYPERTENSIONAHA.113.01018","article-title":"Aggressive blood pressure lowering is dangerous: The J-curve: Con side of the arguement","volume":"63","author":"Verdecchia","year":"2014","journal-title":"Hypertension"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/CRD.0b013e318239b924","article-title":"The evolution and refinement of traditional risk factors for cardiovascular disease","volume":"20","author":"Knowles","year":"2012","journal-title":"Cardiol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","article-title":"The global epidemiology of hypertension","volume":"16","author":"Mills","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/HYPERTENSIONAHA.112.192534","article-title":"\u201cFrom apennines to andes\u201d: Does body mass index affect the relationship between age and blood pressure?","volume":"60","author":"Angeli","year":"2012","journal-title":"Hypertension"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1097\/HJH.0b013e3283625055","article-title":"Hypertension around the world: New insights from developing countries","volume":"31","author":"Angeli","year":"2013","journal-title":"J. Hypertens."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/hr.2013.28","article-title":"Modernization and hypertension: Is the link changing?","volume":"36","author":"Angeli","year":"2013","journal-title":"Hypertens. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/HYPERTENSIONAHA.119.13437","article-title":"Future of Hypertension","volume":"74","author":"Dzau","year":"2019","journal-title":"Hypertension"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: New estimates of R&D costs","volume":"47","author":"DiMasi","year":"2016","journal-title":"J. Health Econ."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1111\/bcp.14825","article-title":"Hypertension: Current trends and future perspectives","volume":"87","author":"Hunter","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1097\/HJH.0000000000000221","article-title":"European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring","volume":"32","author":"Parati","year":"2014","journal-title":"J. Hypertens."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1097\/HJH.0000000000002843","article-title":"2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement","volume":"39","author":"Stergiou","year":"2021","journal-title":"J. Hypertens."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e00396","DOI":"10.1002\/prp2.396","article-title":"Machine learning of big data in gaining insight into successful treatment of hypertension","volume":"6","author":"Koren","year":"2018","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bios.2018.05.034","article-title":"Nanotechnology-based electrochemical detection strategies for hypertension markers","volume":"116","author":"Madhurantakam","year":"2018","journal-title":"Biosens. Bioelectron."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/MNH.0000000000000517","article-title":"Recent advances of biosensors for hypertension and nephrology","volume":"28","author":"Park","year":"2019","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","article-title":"Authors\/Task Force, 2018 ESC\/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension","volume":"36","author":"Williams","year":"2018","journal-title":"J. Hypertens."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International Society of Hypertension Global Hypertension Practice Guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejim.2019.01.016","article-title":"European and US guidelines for arterial hypertension: Similarities and differences","volume":"63","author":"Angeli","year":"2019","journal-title":"Eur. J. Intern. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1161\/CIRCRESAHA.118.314017","article-title":"Keep Blood Pressure Low, but Not Too Much","volume":"123","author":"Verdecchia","year":"2018","journal-title":"Circ. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0300-8932(03)76970-X","article-title":"The Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The weapons are ready","volume":"56","author":"Verdecchia","year":"2003","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2020.09.001","article-title":"The 2020 International Society of Hypertension global hypertension practice guidelines-key messages and clinical considerations","volume":"82","author":"Verdecchia","year":"2020","journal-title":"Eur. J. Intern. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/jhh.2010.113","article-title":"Increased nighttime blood pressure or nondipping profile for prediction of cardiovascular outcomes","volume":"25","author":"Tsioufis","year":"2011","journal-title":"J. Hum. Hypertens."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1161\/01.HYP.24.6.793","article-title":"Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension","volume":"24","author":"Verdecchia","year":"1994","journal-title":"Hypertension"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jama.2019.9811","article-title":"Association of Office and Ambulatory Blood Pressure With Mortality and Cardiovascular Outcomes","volume":"322","author":"Yang","year":"2019","journal-title":"JAMA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1161\/01.HYP.0000172757.96281.bf","article-title":"Effects of time of day of treatment on ambulatory blood pressure pattern of patients with resistant hypertension","volume":"46","author":"Hermida","year":"2005","journal-title":"Hypertension"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3109\/07420528.2010.485411","article-title":"Administration-time-dependent effects of spirapril on ambulatory blood pressure in uncomplicated essential hypertension","volume":"27","author":"Hermida","year":"2010","journal-title":"Chronobiol. Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1093\/eurheartj\/ehaa265","article-title":"Chronotherapy in hypertension: The devil is in the details","volume":"41","author":"Guthrie","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/08037051.2020.1747696","article-title":"Blood pressure medication should not be routinely dosed at bedtime. We must disregard the data from the HYGIA project","volume":"29","author":"Kreutz","year":"2020","journal-title":"Blood Press."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/00004872-199715020-00012","article-title":"The effect on 24 h blood pressure control of an angiotensin converting enzyme inhibitor (perindopril) administered in the morning or at night","volume":"15","author":"Morgan","year":"1997","journal-title":"J. Hypertens."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1161\/HYPERTENSIONAHA.112.200477","article-title":"A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease","volume":"61","author":"Rahman","year":"2013","journal-title":"Hypertension"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e010313","DOI":"10.1136\/bmjopen-2015-010313","article-title":"Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: The Treatment In Morning versus Evening (TIME) study","volume":"6","author":"Rorie","year":"2016","journal-title":"BMJ Open"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1161\/HYPERTENSIONAHA.111.183525","article-title":"Chlorthalidone versus hydrochlorothiazide: A tale of tortoises and a hare","volume":"58","author":"Kaplan","year":"2011","journal-title":"Hypertension"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1161\/HYPERTENSIONAHA.110.156166","article-title":"Chlorthalidone: Don\u2019t call it \u201cthiazide-like\u201d anymore","volume":"56","author":"Kurtz","year":"2010","journal-title":"Hypertension"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa2110730","article-title":"Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease","volume":"385","author":"Agarwal","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): A randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","article-title":"Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: The PATHWAY-2 mechanisms substudies","volume":"6","author":"Williams","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/clc.20324","article-title":"A comparison of the aldosterone-blocking agents eplerenone and spironolactone","volume":"31","author":"Struthers","year":"2008","journal-title":"Clin. Cardiol."},{"key":"ref_46","first-page":"CD008996","article-title":"Eplerenone for hypertension","volume":"2","author":"Tam","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.vph.2005.03.004","article-title":"Vascular endothelin in hypertension","volume":"43","author":"Schiffrin","year":"2005","journal-title":"Vascul. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40119-021-00233-7","article-title":"Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension","volume":"10","author":"Angeli","year":"2021","journal-title":"Cardiol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.lfs.2014.09.009","article-title":"Aging and endothelin: Determinants of disease","volume":"118","author":"Barton","year":"2014","journal-title":"Life Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1016\/j.ydbio.2018.08.014","article-title":"News from the endothelin-3\/EDNRB signaling pathway: Role during enteric nervous system development and involvement in neural crest-associated disorders","volume":"444","author":"Bondurand","year":"2018","journal-title":"Dev. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1006\/bbrc.2000.4180","article-title":"Increased expression of endothelin-1 and inducible nitric oxide synthase isoform II in aging arteries in vivo: Implications for atherosclerosis","volume":"280","author":"Goettsch","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1161\/HYPERTENSIONAHA.115.05267","article-title":"Association studies suggest a key role for endothelin-1 in the pathogenesis of preeclampsia and the accompanying renin-angiotensin-aldosterone system suppression","volume":"65","author":"Verdonk","year":"2015","journal-title":"Hypertension"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/332411a0","article-title":"A novel potent vasoconstrictor peptide produced by vascular endothelial cells","volume":"332","author":"Yanagisawa","year":"1988","journal-title":"Nature"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1161\/HYPERTENSIONAHA.119.14504","article-title":"Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension","volume":"75","author":"Verweij","year":"2020","journal-title":"Hypertension"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1124\/jpet.118.253864","article-title":"Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension","volume":"368","author":"Trensz","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.peptides.2018.05.012","article-title":"Atrial and brain natriuretic peptides: Hormones secreted from the heart","volume":"111","author":"Nakagawa","year":"2019","journal-title":"Peptides"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.biopha.2017.04.024","article-title":"Neprilysin inhibitors: A new hope to halt the diabetic cardiovascular and renal complications?","volume":"90","author":"Malek","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11897-015-0270-8","article-title":"The Role of Neprilysin Inhibitors in Cardiovascular Disease","volume":"12","author":"Mills","year":"2015","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s11906-003-0045-6","article-title":"Recent clinical trials with omapatrilat: New developments","volume":"5","author":"Zanchi","year":"2003","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: A randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2147\/VHRM.S4235","article-title":"Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: Update after recent clinical trials","volume":"5","author":"Reboldi","year":"2009","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e13280","DOI":"10.1111\/apha.13280","article-title":"Anti-fibrotic mechanisms of angiotensin AT2 -receptor stimulation","volume":"227","author":"Sumners","year":"2019","journal-title":"Acta Physiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/CIRCRESAHA.115.304110","article-title":"AT(2) receptor activation induces natriuresis and lowers blood pressure","volume":"115","author":"Kemp","year":"2014","journal-title":"Circ. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1097\/01.hjh.0000251902.85675.7e","article-title":"Angiotensin II\/AT2 receptor-induced vasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cGMP-dependent protein kinase","volume":"24","author":"Savoia","year":"2006","journal-title":"J. Hypertens."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41440-021-00643-z","article-title":"Novel therapeutics for the treatment of hypertension and its associated complications: Peptide- and nonpeptide-based strategies","volume":"44","author":"Ghatage","year":"2021","journal-title":"Hypertens. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/1753944712444866","article-title":"Beyond blood pressure: Evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers","volume":"6","author":"Verdecchia","year":"2012","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/1479164114561992","article-title":"Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences","volume":"12","author":"Gallo","year":"2015","journal-title":"Diab. Vasc. Dis. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0140-6736(11)60207-9","article-title":"Management of type 2 diabetes: New and future developments in treatment","volume":"378","author":"Tahrani","year":"2011","journal-title":"Lancet"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1093\/eurheartj\/ehz687","article-title":"The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: New features and the \u2018Ten Commandments\u2019 of the 2019 Guidelines are discussed by Professor Peter J. Grant and Professor Francesco Cosentino, the Task Force chairmen","volume":"40","author":"Grant","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/HYPERTENSIONAHA.116.07703","article-title":"Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication","volume":"68","author":"Mancia","year":"2016","journal-title":"Hypertension"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e005686","DOI":"10.1161\/JAHA.117.005686","article-title":"Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis","volume":"6","author":"Baker","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e004007","DOI":"10.1161\/JAHA.116.004007","article-title":"Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients","volume":"6","author":"Mazidi","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF01828841","article-title":"Neural control of renal function in health and disease","volume":"4","year":"1994","journal-title":"Clin. Auton. Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1152\/physrev.1997.77.1.75","article-title":"Neural control of renal function","volume":"77","author":"Kopp","year":"1997","journal-title":"Physiol. Rev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1161\/HYPERTENSIONAHA.118.10265","article-title":"Renal Denervation","volume":"72","author":"Singh","year":"2018","journal-title":"Hypertension"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"R245","DOI":"10.1152\/ajpregu.00647.2009","article-title":"Translational medicine: The antihypertensive effect of renal denervation","volume":"298","author":"Esler","year":"2010","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Symplicity HTN-2 Investigators, Esler, M.D., Krum, H., Sobotka, P.A., Schlaich, M.P., Schmieder, R.E., and Bohm, M. (2010). Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): A randomised controlled trial. Lancet, 376, 1903\u20131909.","DOI":"10.1016\/S0140-6736(10)62039-9"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","article-title":"A controlled trial of renal denervation for resistant hypertension","volume":"370","author":"Bhatt","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/S0140-6736(18)31082-1","article-title":"Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): A multicentre, international, single-blind, randomised, sham-controlled trial","volume":"391","author":"Azizi","year":"2018","journal-title":"Lancet"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/S0140-6736(20)30554-7","article-title":"Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): A multicentre, randomised, sham-controlled trial","volume":"395","author":"Bohm","year":"2020","journal-title":"Lancet"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","article-title":"Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial","volume":"391","author":"Kandzari","year":"2018","journal-title":"Lancet"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMc0904179","article-title":"Renal sympathetic-nerve ablation for uncontrolled hypertension","volume":"361","author":"Schlaich","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(15)00259-7","article-title":"Renal denervation for resistant hypertension-Authors\u2019 reply","volume":"386","author":"Azizi","year":"2015","journal-title":"Lancet"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1093\/eurheartj\/ehz118","article-title":"Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry","volume":"40","author":"Mahfoud","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1161\/CIRCULATIONAHA.118.037654","article-title":"A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension (RADIOSOUND-HTN)","volume":"139","author":"Fengler","year":"2019","journal-title":"Circulation"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/eurheartj\/ehaa121","article-title":"Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies","volume":"41","author":"Mahfoud","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40292-020-00367-0","article-title":"Italian Society of Arterial Hypertension (SIIA) Position Paper on the Role of Renal Denervation in the Management of the Difficult-to-Treat Hypertensive Patient","volume":"27","author":"Bruno","year":"2020","journal-title":"High Blood Press. Cardiovasc. Prev."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.2215\/CJN.03070221","article-title":"Renal Denervation for the Treatment of Hypertension: Unnerving or Underappreciated?","volume":"16","author":"Sarathy","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1093\/eurheartj\/eht154","article-title":"Expert consensus document from the European Society of Cardiology on catheter-based renal denervation","volume":"34","author":"Mahfoud","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/j.ijcard.2013.12.270","article-title":"Iatrogenic renal artery stenosis after renal sympathetic denervation","volume":"172","author":"Bacaksiz","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/jch.12482","article-title":"De novo renal artery stenosis after renal sympathetic denervation","volume":"17","author":"Celik","year":"2015","journal-title":"J. Clin. Hypertens."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1016\/j.jcin.2015.05.022","article-title":"Severe Renal Artery Stenosis After Renal Sympathetic Denervation","volume":"8","year":"2015","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1016\/j.jacc.2012.09.027","article-title":"Renal artery stenosis after renal sympathetic denervation","volume":"60","author":"Kaltenbach","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3389\/fphys.2014.00311","article-title":"What is the true incidence of renal artery stenosis after sympathetic denervation?","volume":"5","author":"Wang","year":"2014","journal-title":"Front. Physiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(12)61145-3","article-title":"Secondary rise in blood pressure after renal denervation","volume":"380","author":"Vonend","year":"2012","journal-title":"Lancet"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/eurheartj\/ehu450","article-title":"Renal denervation: Symply trapped by complexity?","volume":"36","author":"Mahfoud","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41371-020-00437-9","article-title":"Treatment of the hypertensive patient in 2030","volume":"35","author":"Bhudia","year":"2021","journal-title":"J. Hum. Hypertens."}],"container-title":["Journal of Cardiovascular Development and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3425\/9\/3\/72\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:31:09Z","timestamp":1760135469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3425\/9\/3\/72"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,3]]},"references-count":105,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["jcdd9030072"],"URL":"https:\/\/doi.org\/10.3390\/jcdd9030072","relation":{},"ISSN":["2308-3425"],"issn-type":[{"value":"2308-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,3]]}}}